Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.
It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.
The company is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -33.72 M Increased by +19.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 - | -24.61 M - | Decreased by N/A% - |
| Mar 31, 25 | 0.00 - | -30.58 M - | Decreased by N/A% - |
| Dec 31, 24 | 0.00 - | -10.54 M - | Decreased by N/A% - |
| Sep 30, 24 | 0.00 - | -41.93 M - | Decreased by N/A% - |